J Clin Invest. 2014 Jun;124(6):2315-24. doi: 10.1172/JCI72272. Epub 2014 Jun 2.
Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.
近年来,在确定常染色体显性多囊肾病(ADPKD)的遗传病因和修饰机制方面取得了进展,有助于解释一些极端的疾病表现和其他表型变异性。对 ADPKD 蛋白、多囊蛋白-1 和 -2 的研究,以及更好地模拟人类疾病的动物模型的开发和特征描述,也帮助我们理解了发病机制,并促进了治疗评估。此外,对 ADPKD 中异常下游途径(如增殖/分泌相关信号、能量代谢和激活的巨噬细胞)的认识不断提高,其中 cAMP 和钙变化可能发挥作用,这导致了治疗靶点的确定。最后,最近和正在进行的临床前和临床试验的结果大大提高了现有有效 ADPKD 治疗方法的前景。